Given the current use of immune checkpoint therapy in the first-line treatment of locally advanced or metastatic PD-L1-positive triple-negative breast carcinoma and a potentially expanding spectrum of therapeutic indications, it seems likely that the prognostic impact of PD-L1 expression on disease outcome in future studies will be different from our findings. This evidence concerns the gene CD274 and triple-negative breast carcinoma.